Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Organization Activities
BIONET Corp. was first established in 1999 as the pioneer company in the field of stem cell application in Taiwan as well as in Asia. BIONET has focused: “Stem Cell Therapy” and “Genetic Testing”. In 2007, BIONET completed initial public offering (TPO: 1784) and became the first publicly traded company in the stem cell and genetic industry of Taiwan. Furthermore, in 2012, Genesis Genetics Asia Corp. (GGA), a subsidiary of BIONET, made its IPO (TPO: 4160) as Taiwan’s first public company specialized in both genetic testing and scientific informatics. BIONET is the largest enterprise that the penetration rate is up to 50% for cell therapy and genetic engineering industry in Taiwan.
Contact Information
Address: No.28, 36 Ln., Xinhu 1st Rd.,
Neihu Dist., Taipei City 11494
Taiwan
Phone: +886-2-2795-1777, Monday to Friday, 9am-6pm CST (UTC+8)
Toll-free: 0800-800-018
Email: service@babybanks.com
Website: www.babybanks.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Tse Wen Chang, internationally recognized as one of the greatest contributors to the biotech field, and founder, CEO, and president of Immunwork, provides insights into the company’s ground-breaking T-E™ pharmaceuticals,…
Ten years after its creation in 2005, InnoPharmax was ranked seventh fastest growing technology company in Taiwan in Deloitte’s “Technology Fast 500 Asia Pacific” annual ranking. CS Hsu, founder and…
Guo-Liang Yu, executive chairman of Crown Bioscience International, on the innovation-driven approach he has instilled since joining in 2013 and how this unique technology platform company now stands as the…
Chuan-Der Huang, founder, president, and CEO of KriSan Biotech, a recently established Taiwan-based service provider focused on new drug process and analytical R&D for small molecules and peptides from Pre-clinical…
Vivian Lee, president and CEO of Linical Taiwan, documents the affiliate’s main milestones since its establishment in 2013, its strategic positioning among the Linical Group as a regional hub, as…
Terry Lin, general manager, and Freia Wei, director for international business at UniPharma, on the company’s move from specialty distribution to drug development and diagnostic products. With an upcoming IPO,…
Yita Lee & Muh-Hwan Su of Sinphar Group & SynCore Bio describe the exciting R&D projects of SynCore Bio, the oncology & dry AMD focused innovation-driven company of the group,…
Jonas Wang Ph.D., Chairman and CEO of StemCyte, a global leader in Regenerative Therapy field including cell processing and transplantation located in the US, Taiwan, and India, provides us with…
In an exclusive interview conducted on the 22nd of December 2016, Taiwan’s Minister of Health and Welfare Lin Tzou-yien discussed improving Taiwan’s National Health Insurance (NHI), ensuring that Taiwanese patients…
The co-founder and president of Mycenax Biotech, Dr. Karen Wen details the key lessons learned from the development of their first in-house product TuNEX® and how they have been applied…
Howard Lee, chairman and CEO of Easywell Biomedicals, documents the most exciting R&D projects that will drive the company to new heights; spanning from a life-changing Parkinson’s transdermal patch to…
Chih-Kung Lee, Minister of Economic Affairs of the Republic of China (Taiwan) provides insights into Taiwan’s “new economic model” recently established by the new government to boost the country’s economic…
See our Cookie Privacy Policy Here